Cover Image
市場調查報告書

何杰金氏淋巴瘤:開發平台分析

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232775
出版日期 內容資訊 英文 376 Pages
訂單完成後即時交付
價格
Back to Top
何杰金氏淋巴瘤:開發平台分析 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 376 Pages
簡介

何杰金氏淋巴瘤是淋巴系統組織的癌症之一,在淋巴節和脾臟,肝臟,骨髓等地方出現。患者的年齡層約15∼30歲,以及50∼70歲佔大半。部分病例,據信是因EB病毒(EBV)的感染經歷而發病。還有具HIV感染經歷比起普通人發病風險也變高。主要的症狀為伴隨頸部、腋下、鼠蹊部的淋巴節疼痛的腫脹,及發熱、發冷,盜汗,體重減輕,食慾衰退,皮膚發癢等。主要的治療方法,有外科手術和放射治療、化療等。

本報告提供全球各國的何杰金氏淋巴瘤治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

何杰金氏淋巴瘤概要

治療藥的開發

  • 何杰金氏淋巴瘤開發中產品:概要
  • 何杰金氏淋巴瘤開發中產品:比較分析

各企業開發中的何杰金氏淋巴瘤治療藥

大學/研究機關研究中的何杰金氏淋巴瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

何杰金氏淋巴瘤治療藥:開發中的產品一覽(各企業)

何杰金氏淋巴瘤治療藥:研究中的產品一覽(各大學/研究機關)

何杰金氏淋巴瘤開發治療藥的企業

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.
  • ADC Therapeutics Sarl
  • Affimed Therapeutics AG
  • Arbutus Biopharma Corporation
  • Bellicum Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cell Medica Limited
  • Cellular Biomedicine Group, Inc.
  • Constellation Pharmaceuticals, Inc.
  • Curis, Inc.
  • Faron Pharmaceuticals Oy
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Mirati Therapeutics Inc.
  • Molecular Templates Inc.
  • NantKwest, Inc.
  • Novartis AG
  • 小野藥品工業
  • Pfizer Inc.
  • Pharmacyclics, Inc.
  • Philogen S.p.A.
  • Rich Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Selvita S.A.
  • Sigma-Tau S.p.A.
  • Spectrum Pharmaceuticals, Inc.
  • Stemline Therapeutics, Inc.
  • Syndax Pharmaceuticals, Inc.
  • 武田藥品工業
  • TG Therapeutics, Inc.
  • Theravectys SA
  • Trillium Therapeutics Inc.

何杰金氏淋巴瘤:治療藥的評估

  • 單劑治療藥的情況
  • 組合產品
  • 各標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (INCB-039110 + INCB-040093)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • abexinostat hydrochloride
  • acalisib
  • ADCT-301
  • AFM-13
  • Alocrest
  • aNK Program
  • azacitidine
  • BMS-986016
  • BPX-501
  • burentsukishimabubedochin
  • CBM-C30.1
  • 何杰金氏病、非何杰金氏淋巴瘤的細胞免疫療法
  • 腫瘤學細胞免疫療法
  • 何杰金氏病、非何杰金氏淋巴瘤 CD30標的之細胞免疫療法
  • 何杰金氏淋巴瘤、慢性淋巴性白血病GM-CSF標的之細胞免疫療法
  • EB病毒相關腫瘤、感染疾病LMP/BARF-1/EBNA1標的之細胞免疫療法
  • 腫瘤學、感染疾病疾病LMP-1/LMP-2標的之細胞免疫療法
  • 腫瘤學、滑薄膜肉瘤XNY-ESO-1/MAGEA4/PRAME/surubibin標的之細胞免疫療法
  • CMD-003
  • CPI-0610
  • CUDC-907
  • entinostat
  • EB病毒疫苗
  • Ferritarg
  • FP-1304
  • FT-1050
  • haNK Program
  • INCB-40093
  • Indimitecan
  • Indotecan hydrochloride
  • Iomab-B
  • ipilimumab
  • ixazomib citrate
  • lirilumab
  • MK-2206
  • mocetinostat
  • 血液系統腫瘤的PD-1/PD-L1阻礙單株抗體
  • 腫瘤學的CD45標的單株抗體複合體
  • NiCord
  • nivolumab
  • NSC-678515
  • Panobinostat
  • pembrolizumab
  • PF-06801591
  • PNK-007
  • procarbazine hydrochloride
  • radretumab
  • 黑色素瘤、何杰金氏淋巴瘤用組換蛋白質
  • resminostat
  • ricolinostat
  • RP-323
  • ruxolitinib phosphate
  • SEL-24B489
  • SL-101
  • SL-501
  • temsirolimus
  • TGR-1202
  • TKM-PLK1
  • TTI-621
  • 鼻咽癌、何杰金氏淋巴瘤用疫苗

何杰金氏淋巴瘤治療藥:開發中產品的最新趨勢

何杰金氏淋巴瘤治療藥:開發暫停的產品

何杰金氏淋巴瘤治療藥:開發中止的產品

何杰金氏淋巴瘤相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8349IDB

Summary

Global Markets Direct's, 'Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016', provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
  • The report reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects
  • The report assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Overview
  • Therapeutics Development
    • Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
    • Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics under Development by Companies
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics under Investigation by Universities/Institutes
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Products under Development by Companies
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Products under Investigation by Universities/Institutes
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
    • 4SC AG
    • AbbVie Inc
    • Acetylon Pharmaceuticals, Inc.
    • Actinium Pharmaceuticals, Inc.
    • ADC Therapeutics Sarl
    • Affimed GmbH
    • Amgen Inc.
    • Arno Therapeutics, Inc.
    • Bellicum Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Cell Medica Limited
    • Cellular Biomedicine Group, Inc.
    • Constellation Pharmaceuticals, Inc.
    • Curis, Inc.
    • Faron Pharmaceuticals Oy
    • Gamida Cell Ltd.
    • Incyte Corporation
    • Merck & Co., Inc.
    • Merck KGaA
    • Mesoblast Limited
    • Millennium Pharmaceuticals Inc
    • Mirati Therapeutics Inc.
    • Molecular Templates Inc.
    • NantKwest, Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • Philogen S.p.A.
    • Polyphor Ltd.
    • Rich Pharmaceuticals, Inc.
    • Seattle Genetics, Inc.
    • Selvita S.A.
    • Sigma-Tau S.p.A.
    • Spectrum Pharmaceuticals, Inc.
    • Stemline Therapeutics, Inc.
    • Taiwan Liposome Company, Ltd.
    • Takeda Pharmaceutical Company Limited
    • TG Therapeutics, Inc.
    • Theravectys SA
    • TRACON Pharmaceuticals, Inc.
    • Trillium Therapeutics Inc.
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (INCB-039110 + INCB-040093) - Drug Profile
    • ADCT-301 - Drug Profile
    • AFM-13 - Drug Profile
    • Alocrest - Drug Profile
    • AR-42 - Drug Profile
    • avelumab - Drug Profile
    • azacitidine - Drug Profile
    • balixafortide - Drug Profile
    • BC-8Y90 - Drug Profile
    • BMS-986016 - Drug Profile
    • BPX-501 - Drug Profile
    • brentuximab vedotin - Drug Profile
    • CBM-C30.1 - Drug Profile
    • Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
    • Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
    • Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile
    • Cellular Immunotherapy to Target GM-CSF for Solid Tumor and Hematological Cancer - Drug Profile
    • Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile
    • Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
    • Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile
    • CMD-003 - Drug Profile
    • CPI-0610 - Drug Profile
    • CUDC-907 - Drug Profile
    • Epstein-Barr virus vaccine - Drug Profile
    • Ferritarg - Drug Profile
    • FP-1305 - Drug Profile
    • haNK Program - Drug Profile
    • ibrutinib - Drug Profile
    • INCB-40093 - Drug Profile
    • Indimitecan - Drug Profile
    • Indotecan hydrochloride - Drug Profile
    • Iomab-B - Drug Profile
    • ipilimumab - Drug Profile
    • ixazomib citrate - Drug Profile
    • lirilumab - Drug Profile
    • MK-2206 - Drug Profile
    • mocetinostat - Drug Profile
    • Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile
    • MPC-CBE - Drug Profile
    • MT-17000 - Drug Profile
    • NiCord - Drug Profile
    • nivolumab - Drug Profile
    • NL-101 - Drug Profile
    • ONX-0801 - Drug Profile
    • pembrolizumab - Drug Profile
    • PF-06801591 - Drug Profile
    • PNK-007 - Drug Profile
    • procarbazine hydrochloride - Drug Profile
    • radretumab - Drug Profile
    • resminostat - Drug Profile
    • ricolinostat - Drug Profile
    • RP-323 - Drug Profile
    • ruxolitinib phosphate - Drug Profile
    • sapanisertib - Drug Profile
    • SEA-CD40 - Drug Profile
    • SEL-24B489 - Drug Profile
    • SL-101 - Drug Profile
    • SL-501 - Drug Profile
    • Small Molecule to Inhibit ADAM-10 for Hodgkin Lymphoma - Drug Profile
    • temsirolimus - Drug Profile
    • TGR-1202 - Drug Profile
    • TRC-102 - Drug Profile
    • TTI-621 - Drug Profile
    • Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile
    • vinorelbine tartrate - Drug Profile
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2016
  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by 4SC AG, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics Sarl, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH , H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Amgen Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Arno Therapeutics, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celgene Corporation, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cell Medica Limited, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Curis, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Faron Pharmaceuticals Oy, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Gamida Cell Ltd., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Incyte Corporation, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck & Co., Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck KGaA, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mesoblast Limited, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mirati Therapeutics Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Molecular Templates Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NantKwest, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Pfizer Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Philogen S.p.A., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Polyphor Ltd., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rich Pharmaceuticals, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Seattle Genetics, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Selvita S.A., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sigma-Tau S.p.A., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Stemline Therapeutics, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TG Therapeutics, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Theravectys SA, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Trillium Therapeutics Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..1), H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..2), H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..3), H2 2016
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2016
  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top